Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
The estimated costs of managing VEGFR TKI class-effect AEs were lowest with tivozanib, and highest with lenvatinib and everolimus, indicating potentially differential healthcare resource burden by TKI regimen. The use of tivozanib in the 3 L + mRCC setting suggests potential costs offsets when compared to other TKI regimens.
Authors
- Vijay Kasturi
- Jeffrey T. Yorio (ORCID: https://orcid.org/0000-0002-2750-2823)
- Aviva G. Asnis-Alibozek
- Thomas E. Hutson (ORCID: https://orcid.org/0000-0002-4529-4212)
Institutions
- Texas A&M Health Science Center (US)
- University of California, Irvine (US)
- Texas Oncology (US)
- AVEO Oncology (United States) (US)
- Balcones Technologies (United States) (US)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1186/s12913-024-11587-8
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- LG Chem